Adapting the Elixhauser comorbidity index for cancer patients-Reference-Cited by-同舟云学术

Adapting the Elixhauser comorbidity index for cancer patients

Published:2018-02-01 Issue:9 Volume:124 Page:2018-2025
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Mehta Hemalkumar B.¹^ORCID,Sura Sneha D.²,Adhikari Deepak³,Andersen Clark R.⁴,Williams Stephen B.⁵^ORCID,Senagore Anthony J.¹,Kuo Yong-Fang⁴,Goodwin James S.⁶

Affiliation:

1. Department of Surgery; University of Texas Medical Branch; Galveston Texas

2. Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy; University of Houston; Houston Texas

3. School of Public Health; Brown University; Providence Rhode Island

4. Department of Preventive Medicine and Community Health; University of Texas Medical Branch; Galveston Texas

5. Division of Urology, Department of Surgery; University of Texas Medical Branch; Galveston Texas

6. Department of Internal Medicine; University of Texas Medical Branch; Galveston Texas

Funder

Cancer Prevention and Research Institute of Texas

National Cancer Institute

Agency for Healthcare Research and Quality

the National Center for Advancing Translational Sciences of the National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference23 articles.

1. The impact of comorbidity on cancer and its treatment;Sarfati;CA Cancer J Clin.,2016

2. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation;Charlson;J Chronic Dis.,1987

3. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients;Klabunde;Ann Epidemiol.,2007

4. Comorbidity measures for use with administrative data;Elixhauser;Med Care.,1998

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy;JNCI Cancer Spectrum;2024-08-12

2. Comorbidities in Hispanic/Latino Veterans with epilepsy;Epilepsy & Behavior;2024-08

3. Racial–Ethnic Comparison of Treatment for Papillary Thyroid Cancer in the Military Health System;Annals of Surgical Oncology;2024-07-31

4. Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers;The Oncologist;2024-06-21

5. Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide;Acta Oncologica;2024-04-09